ASND
$221.88-1.95 (-0.87%)
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Denmark, rest of Europe, North America, and internationally.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Denmark, rest of Europe, North America, and internationally. The company offers SKYTROFA for treating pediatri...
Recent News
Ascendis Pharma Trial Wins And Valuation Gap Draw Investor Attention
Ascendis Pharma reported positive Week 52 data for once weekly TransCon hGH in prepubertal children with Turner syndrome. The company also released new Week 104 outcomes for TransCon CNP, branded as YUVIWEL, in children with achondroplasia. YUVIWEL is already approved by the FDA, with an EU submission planned. This highlights growing regulatory momentum around these pediatric programs. For investors tracking NasdaqGS:ASND, these back to back trial readouts add fresh clinical detail around...
Agriculture Stock Up 53% Draws $12 Million Bet. Here's What Long-Term Investors Should Know
This agribusiness firm delivers grain, renewables, and plant nutrient solutions to commercial and industrial clients worldwide.
Ascendis Pharma Gains FDA Nod For Yuviwel And New Growth Prospects
FDA granted accelerated approval for Yuviwel, a once-weekly therapy for children with achondroplasia. Yuviwel is the first weekly option in this indication, ending a competitor's monopoly with a daily treatment. The approval includes a Rare Pediatric Disease Priority Review Voucher, adding potential value for Ascendis Pharma. This decision positions Ascendis Pharma (NasdaqGS:ASND) as a key player in achondroplasia treatment. Ascendis Pharma, listed on NasdaqGS:ASND, focuses on rare...
Ascendis Pharma Details Early Q2 YUVIWEL Launch Plan, Pricing Tease at TD Cowen Conference
Ascendis Pharma A/S (NASDAQ:ASND) discussed plans to launch its newly approved achondroplasia therapy YUVIWEL during a virtual fireside chat at the 46th annual TD Cowen Healthcare Conference, held shortly after the company’s U.S. approval announcement. YUVIWEL launch timing and readiness Management
Ascendis Pharma Maps 2026 U.S. Launch of Once-Weekly YUVIWEL After FDA Approval in Achondroplasia
Ascendis Pharma A/S (NASDAQ:ASND) executives outlined plans for the U.S. launch of YUVIWEL following FDA approval, describing the product as the first once-weekly treatment for children with achondroplasia and emphasizing its label, clinical profile, and expected near-term commercialization steps.